- Report
- February 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,124GBP
- Report
- July 2023
- 55 Pages
Global
From €2354EUR$2,450USD£2,021GBP
- Report
- November 2023
- 650 Pages
Global
From €4804EUR$5,000USD£4,124GBP
- Report
- November 2023
- 178 Pages
Global
From €4708EUR$4,900USD£4,042GBP
- Drug Pipelines
- April 2024
- 190 Pages
Global
From €2883EUR$3,000USD£2,474GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1201EUR$1,250USD£1,031GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €2883EUR$3,000USD£2,474GBP
- Report
- July 2022
- 263 Pages
Global
From €1800EUR$2,007USD£1,599GBP
- Report
- May 2022
- 50 Pages
Global
From €500EUR$557USD£444GBP
- Report
- January 2021
- 125 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- December 2021
- 353 Pages
Global
From €2642EUR$2,750USD£2,268GBP
€5285EUR$5,500USD£4,537GBP
- Report
- July 2019
- 21 Pages
Global
From €601EUR$625USD£516GBP
€1201EUR$1,250USD£1,031GBP
- Report
- April 2023
- 110 Pages
Global
From €4564EUR$4,750USD£3,918GBP
- Report
- April 2023
- 500 Pages
Global
From €3123EUR$3,250USD£2,681GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,186GBP
- Drug Pipelines
- December 2019
- 134 Pages
Global
From €3363EUR$3,500USD£2,887GBP
- Report
- May 2022
- 91 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- May 2022
- 66 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Book
- October 2013
- 304 Pages
The Tumor Antigen market is a subset of the Oncology Drugs market, which focuses on the development of drugs to treat cancer. Tumor antigens are molecules that are expressed on the surface of cancer cells and can be recognized by the immune system. These antigens can be used to develop drugs that target and destroy cancer cells, while leaving healthy cells unharmed. Tumor antigens can be used to develop vaccines, monoclonal antibodies, and other immunotherapies. These therapies can be used to treat a variety of cancers, including breast, lung, and colorectal cancer.
Some companies in the Tumor Antigen market include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Roche. These companies are actively researching and developing new treatments for cancer, including immunotherapies that target tumor antigens. Show Less Read more